Objective To investigate the diagnostic value of contrast-enhanced ultrasound combined with serum long non-coding RNA(lncRNA) prostate cancer-associated transcript 6(PCAT6) detection in breast cancer.
Methods A total of 72 patients with breast cancer were selected as breast cancer group, and 68 patients with benign breast diseases were selected as breast benign disease group.The contrast-enhanced ultrasound were performed in two groups, and the serum levels of lncRNA PCAT6 and carbohydrate antigen 153(CA153) levels were detected.The value of contrast-enhanced ultrasound and serum levels of lncRNA PCAT6 and CA153 in the diagnosis of breast cancer were analyzed.
Results The proportions of high enhancement and lesion enlargement in breast cancer group were significanthy higher than those in benign breast disease group(P < 0.01).The sensitivity, specificity and accuracy of contrast-enhanced ultrasound in the diagnosis of breast cancer were 73.61%, 89.71% and 81.43%, respectively.The serum levels of lncRNA PCAT6 and CA153 in the breast cancer group were significantly higher than those in benign breast disease group(P < 0.01).The AUC, cut-off value, sensitivity, specificity and accuracy of serum lncRNA PCAT6 and CA153 in the diagnosis of breast cancer were (0.882 and 0.719), (1.56 and 27.28 U/mL), (76.39% and 61.11%).The sensitivity, specificity and accuracy of contrast-enhanced ultrasound combined with serum lncRNA PCAT6 in the diagnosis of breast cancer were 98.61%, 86.76% and 92.86%, respectively.
Conclusions The contrast-enhanced ultrasound combined with serum lncRNA PCAT6 detection has high value in the diagnosis of breast cancer, and it is expected to become a clinical reference scheme for early diagnosis of breast cancer.
DownLoad: